Drug intelligence / Profile preview

atorvastatin + losartan

Development stage: Phase 1
Lead developer: HanAll BioPharma
Modality: Small Molecules
Administration: Oral

Overview

HL-040XC is a fixed-dose combination tablet containing atorvastatin (a HMG-CoA reductase inhibitor, or statin) and losartan (an angiotensin II receptor blocker, ARB). It is developed for the treatment of patients with both essential hypertension and hyperlipidemia. Atorvastatin lowers cholesterol by inhibiting HMG-CoA reductase, while losartan lowers blood pressure by blocking the angiotensin II type 1 receptor. The combination aims to address both cardiovascular risk factors in a single therapy[3][4][5][7].

Brand names: Ato-Losar
Other names: atorvastatin calcium/losartan potassium

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on atorvastatin + losartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atorvastatin + losartan.

Explore the full profile